You so like it’s actually a very broad question because like there are many biomarkers like that that are being studied some of them are circulating biomarkers some of them are like tissue-based biomarkers that I’m studying and some of the tissue-based biomarkers are based on the tumor itself and some of them are like tumor microenvironment uh like I am a little bit biased on this...
You so like it’s actually a very broad question because like there are many biomarkers like that that are being studied some of them are circulating biomarkers some of them are like tissue-based biomarkers that I’m studying and some of the tissue-based biomarkers are based on the tumor itself and some of them are like tumor microenvironment uh like I am a little bit biased on this. I think that like tumor microenvironment biomarkers are kind of like the most important ones right now. They show really nice promising results. Studying both the lymphocytes, the macrophages or like other tumor microenvironment elements like fibroblasts dendritic cells, they are really promising. But on the other hand, the field is really progressing very rapidly in the ccRCC. We have now tools like spatial transcriptomics or very high-resolution single-cell RNA sequencing, which could be really helpful in selecting patients for ICI therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
